Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review.

IF 1.6 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2026-07-05 DOI:10.1111/ajd.70178

Julie Phan, Christopher Tran, Shweta Srinivasa, Deshan F Sebaratnam

引用次数: 0

Abstract

The phosphoinositide 3-kinase alpha inhibitor alpelisib has been increasingly used in the treatment of venous malformations. In this systematic review of 47 patients with a molecular diagnosis for their venous malformations treated with alpelisib, a partial or complete radiological response was achieved by 77% of evaluable patients and symptomatic improvement in 98%. Adverse effects were predominantly mild, with hyperglycaemia the most frequent, occurring in 58% of patients with available safety data. TRIAL REGISTRATION: PROSPERO Registration: CRD420261339549.

查看原文本刊更多论文

Alpelisib治疗TEK-和pik3ca相关静脉畸形：系统综述。

磷酸肌肽3-激酶α抑制剂alpelisib已越来越多地用于治疗静脉畸形。在这篇系统综述中，47名接受alpelisib治疗的静脉畸形分子诊断的患者中，77%的可评估患者达到部分或完全放射反应，98%的患者症状改善。不良反应主要是轻微的，高血糖是最常见的，有安全数据的患者中有58%发生了高血糖。试验注册：PROSPERO注册号：CRD420261339549。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.